{
    "title": "109_s1840",
    "content": "SECTION 1. SHORT TITLE.\n\n     This Act may be cited as the ``Safety Net Inpatient Drug \nAffordability Act''.\n\nSEC. 2. EXTENSION OF DISCOUNTS TO INPATIENT DRUGS.\n\n    (a) In General.--Section 340B(b) of the Public Health Service Act \n(42 U.S.C. 256b(b)) is amended by inserting before the period the \nfollowing: ``, except that, notwithstanding the limiting definition set \nforth in section 1927(k)(3) of the Social Security Act, the terms \n`covered outpatient drug' and `covered drug' include any inpatient or \noutpatient drug purchased by a hospital described in subsection \n(a)(4)(L)''.\n    (b) Payment of Medicaid Rebates on Inpatient Drugs.--Section \n340B(c) of such Act (42 U.S.C. 256b(c)) is amended to read as follows:\n    ``(c) Payment of Medicaid Rebates on Inpatient Drugs.--\n            ``(1) In general.--For the cost reporting period covered by \n        the most recently filed Medicare cost report, a hospital \n        described in subsection (a)(4)(L) shall provide to each State \n        with an approved State plan under title XIX of such Act--\n                    ``(A) a rebate on the estimated annual costs of \n                single source and innovator multiple source drugs \n                provided to Medicaid recipients for inpatient use; and\n                    ``(B) a rebate on the estimated annual costs of \n                noninnovator multiple source drugs provided to Medicaid \n                recipients for inpatient use.\n            ``(2) Calculations of rebates.--\n                    ``(A) Single source and innovator multiple source \n                drugs.--For purposes of paragraph (1)(A)--\n                            ``(i) the rebate under such paragraph shall \n                        be calculated by multiplying the estimated \n                        annual costs of single source and innovator \n                        multiple source drugs provided to Medicaid \n                        recipients for inpatient use by the minimum \n                        rebate percentage described in section \n                        1927(c)(1)(B) of the Social Security Act;\n                            ``(ii) the estimated annual costs of single \n                        source drugs and innovator multiple source \n                        drugs provided to Medicaid recipients for \n                        inpatient use under clause (i) shall be equal \n                        to the product of--\n                                    ``(I) the hospital's actual \n                                acquisition costs of all drugs \n                                purchased during the cost reporting \n                                period for inpatient use;\n                                    ``(II) the Medicaid inpatient drug \n                                charges as reported on the hospital's \n                                most recently filed Medicare cost \n                                report divided by total inpatient drug \n                                charges reported on the cost report; \n                                and\n                                    ``(III) the percent of the \n                                hospital's annual inpatient drug costs \n                                described in subclause (I) arising out \n                                of the purchase of single source and \n                                innovator multiple source drugs; and\n                            ``(iii) the terms `single source drug' and \n                        `innovator multiple source drug' have the \n                        meanings given such terms in section 1927(k)(7) \n                        of the Social Security Act.\n                    ``(B) Noninnovator multiple source drugs.--For \n                purposes of subparagraph (1) (B)--\n                            ``(i) the rebate under such paragraph shall \n                        be calculated by multiplying the estimated \n                        annual costs of noninnovator multiple source \n                        drugs provided to Medicaid recipients for \n                        inpatient use by the applicable percentage as \n                        defined in section 1927(c)(3)(B) of the Social \n                        Security Act;\n                            ``(ii) the estimated annual costs of \n                        noninnovator multiple source drugs provided to \n                        Medicaid recipients for inpatient use shall be \n                        equal to the product of--\n                                    ``(I) the hospital's actual \n                                acquisition cost of all drugs purchased \n                                during the cost reporting period for \n                                inpatient use;\n                                    ``(II) the Medicaid inpatient drug \n                                charges as reported on the hospital's \n                                most recently filed Medicare cost \n                                report divided by total inpatient drug \n                                charges reported on the cost report; \n                                and\n                                    ``(III) the percent of the \n                                hospital's annual inpatient drug costs \n                                described in subclause (I) arising out \n                                of the purchase of noninnovator \n                                multiple source drugs; and\n                            ``(iii) the term `noninnovator multiple \n                        source drug' has the meaning given such term in \n                        section 1927(k)(7) of the Social Security Act.\n            ``(3) Payment deadline.--The rebates provided by a hospital \n        under paragraph (1) shall be paid within 90 days of the filing \n        of the hospital's most recently filed Medicare cost report.\n            ``(4) Offset against medical assistance.--Amounts received \n        by a State under this subsection in any quarter shall be \n        considered to be a reduction in the amount expended under the \n        State plan in the quarter for medical assistance for purposes \n        of section 1903(a)(1) of the Social Security Act.''.\n    (c) Clarification That Group Purchasing Prohibition for Certain \nHospitals Is Not Applicable to Inpatient Drugs.--Section \n340B(a)(4)(L)(iii) of such Act (42 U.S.C. 256b(a)(4)(L)(iii)) is \namended by inserting ``(not including such drugs purchased for \ninpatient use)'' after ``covered outpatient drugs''.\n\nSEC. 3. PROVIDING ACCESS TO DISCOUNTED DRUG PRICES FOR CRITICAL ACCESS \n              HOSPITALS.\n\n    (a) In General.--Section 340B of the Public Health Service Act (42 \nU.S.C. 256b) is amended--\n            (1) in subsection (a)(4), by adding at the end the \n        following:\n                    ``(M) An entity that--\n                            ``(i) is a critical access hospital (as \n                        determined under section 1820(c)(2) of the \n                        Social Security Act); and\n                            ``(ii) does not obtain covered outpatient \n                        drugs though a group purchasing organization or \n                        other group purchasing arrangement (not \n                        including such drugs purchased for inpatient \n                        use).'';\n            (2) in subsection (b), as amended by section 2(a), by \n        inserting ``or subsection (a)(4)(M)'' after ``subsection \n        (a)(4)(L)''; and\n            (3) in subsection (c)(1), as added by inserting ``or \n        subsection (a)(4)(M)'' after ``subsection (a)(4)(L)''.\n    (b) Exclusion From Medicaid Best Price Calculations.--Section \n1927(c)(1)(C)(i)(I) of the Social Security Act (42 U.S.C. 1396r-\n8(c)(1)(C)(i)(I)) is amended by inserting ``and to critical access \nhospitals described in section 340B(a)(4)(M) of such Act'' after \n``Public Health Service Act''.\n    (c) Effective Date.--The amendments made by this section shall \napply to drugs purchased on or after January 1, 2006."
}